-+ 0.00%
-+ 0.00%
-+ 0.00%

BioRestorative publishes investor presentation on BRTX-100 stem cell therapy for lumbar disc disease

PUBT·04/24/2026 02:55:16
Listen to the news
BioRestorative publishes investor presentation on BRTX-100 stem cell therapy for lumbar disc disease
  • BioRestorative highlighted BRTX-100, autologous bone marrow-derived mesenchymal stem cell therapy in late-stage Phase 2 development for chronic lumbar disc disease.
  • Phase 2 trial is fully enrolled with 105 subjects in a 2:1 randomization.
  • Company expects topline Phase 2 data in spring 2027.
  • BioRestorative outlined BioCosmeceuticals, secretome-derived skincare platform targeting professional aesthetics, medical-grade skincare, at-home use.
  • ThermoStem preclinical program uses brown adipose-derived stem cells to target obesity, Type 2 diabetes, metabolic disorders.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioRestorative Therapies Inc. published the original content used to generate this news brief on April 23, 2026, and is solely responsible for the information contained therein.